Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
Vivitrol dosing and administration
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
In vitro modeling of central nervous system myelination and remyelination.
Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia.
The value of specialty pharmaceuticals - a systematic review.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Demyelination: the role of reactive oxygen and nitrogen species.
Embryonic stem cell lines derived from human blastocysts.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease.
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Magnetic Resonance Imaging of Optic Neuritis in Patients With Neuromyelitis Optica Versus Multiple Sclerosis.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.

Pages